Gokulnath, et al. Consensus on the use of DPP4 Inhibitors ...
DPP4-Inhibition and Coronary Artery Disease
description
Transcript of DPP4-Inhibition and Coronary Artery Disease
![Page 1: DPP4-Inhibition and Coronary Artery Disease](https://reader036.fdocuments.in/reader036/viewer/2022062222/568163e6550346895dd54932/html5/thumbnails/1.jpg)
DPP4-Inhibition and Coronary Artery Disease
Mary Anne Lim-Abrahan, MD, FPCP, FPSEMProfessor, Endocrinology, Diabetes & MetabolismDept. of Medicine, UP College of Medicine
![Page 2: DPP4-Inhibition and Coronary Artery Disease](https://reader036.fdocuments.in/reader036/viewer/2022062222/568163e6550346895dd54932/html5/thumbnails/2.jpg)
DPP-4 Inhibition and CAD
• The Heart in Diabetes-- Epidemiology-- Energy needs of the Heart
• The Role of Incretins in the Cardiovascular Continuum - Effects on risk factors, LVH ischemia,
AMI, remodeling, CHF and survival
• Mechanisms for GLP-1 Cardioprotection
![Page 3: DPP4-Inhibition and Coronary Artery Disease](https://reader036.fdocuments.in/reader036/viewer/2022062222/568163e6550346895dd54932/html5/thumbnails/3.jpg)
Admission Glucose and Mortality
M Kosiborod et al. Circulation 2005;111;3078-3086.
N=141,680 Medicare patients discharged 1/94 – 12/96
![Page 4: DPP4-Inhibition and Coronary Artery Disease](https://reader036.fdocuments.in/reader036/viewer/2022062222/568163e6550346895dd54932/html5/thumbnails/4.jpg)
Men Women
% M
orta
lity
1-Year Mortality in Diabetic and Nondiabetic Subjects after a First MI
Miettinen H et al. Diabetes Care 1998;21:69-75
![Page 5: DPP4-Inhibition and Coronary Artery Disease](https://reader036.fdocuments.in/reader036/viewer/2022062222/568163e6550346895dd54932/html5/thumbnails/5.jpg)
Diabetes Doubles Early MI Mortality; Despite in Advances in Cardiac Care
Braunwald NEJM 1997;337:1360-69
Defribillation Hemodynamic
monitoring“LYTIC”
ReperfusionBeta-blockade
Aspirin
(before 1962) (1962-1984) (1984-1999)(2000-present)
![Page 6: DPP4-Inhibition and Coronary Artery Disease](https://reader036.fdocuments.in/reader036/viewer/2022062222/568163e6550346895dd54932/html5/thumbnails/6.jpg)
Diabetes and IGT are present in AMI
Consecutive patients with AMI- n=181. OGTT done in all. The 80% after OGTT
25% DM by OGTT 35% IGT by OGTT 40% normal by OGTT
• If all patients are tested= 2/3 of non diabetics- we are not doing anything about it
Norhammar A Lancet 2002; 357: 2140-44
Diabetics excluded
No diabetes by history
![Page 7: DPP4-Inhibition and Coronary Artery Disease](https://reader036.fdocuments.in/reader036/viewer/2022062222/568163e6550346895dd54932/html5/thumbnails/7.jpg)
DIABETIC HEART DISEASEMechanisms
Diabetic Heart Disease
1. Abn load dueto arterial disease
2. Metabolic Effects due to FFA, Insulin resistance
3. Structural – Myocardial fibrosis and ECM changes
5. Autonomic dysfunction due to reduced HR
4. Reduced perfusion due to small vessel disease
Assuming subclinical CAD and LVH excludedFang et al. Endocr Rev2004
![Page 8: DPP4-Inhibition and Coronary Artery Disease](https://reader036.fdocuments.in/reader036/viewer/2022062222/568163e6550346895dd54932/html5/thumbnails/8.jpg)
Diabetes, Insulin Resistance and the Risk of Developing Heart Failure
• Type 2 diabetes independently confers ~2- fold ↑ risk in men and 3-5-fold ↑ risk in women1234
• Insulin resistance independently confers ~1.5 increase in risk5
• Both diabetes and IR have a synergistic interaction with other risk factors, especially HTN and CAD
1Kannel et al, Am J Cardiol 1974; 2Levy et al, JAMA 1996; 3Gottdiener et al, J Am Coll Cardiol 2000; 4Nichols et al, Diabetes Care 2001; 5Ingelsson et al, JAMA 2005
![Page 9: DPP4-Inhibition and Coronary Artery Disease](https://reader036.fdocuments.in/reader036/viewer/2022062222/568163e6550346895dd54932/html5/thumbnails/9.jpg)
Diastolic Dysfunction in DM
• DD is most frequently identified in diabetic patients with normal systolic function as an incidental finding at echocardiography
• Complaints include dyspnea, limited exercise capacity often ascribed to obesity or deconditioning and not recognized as a symptom.
• Delayed or impaired relaxation is earliest and most common change .
![Page 10: DPP4-Inhibition and Coronary Artery Disease](https://reader036.fdocuments.in/reader036/viewer/2022062222/568163e6550346895dd54932/html5/thumbnails/10.jpg)
Kaplan-Meier Analysis of DiastolicDysfunction and Subsequent HF in Diabetic Patients
Aron, M JACC 55, No. 4, 2010
![Page 11: DPP4-Inhibition and Coronary Artery Disease](https://reader036.fdocuments.in/reader036/viewer/2022062222/568163e6550346895dd54932/html5/thumbnails/11.jpg)
Kaplan-Meier Analysis of DiastolicDysfunction and Death in Diabetic Patients
Aron, M JACC 55, No. 4, 2010
![Page 12: DPP4-Inhibition and Coronary Artery Disease](https://reader036.fdocuments.in/reader036/viewer/2022062222/568163e6550346895dd54932/html5/thumbnails/12.jpg)
Energy Needs of the Heart
Continuous need for largeamounts of ATP
Heart turns over 5 kg/day ofATP(!) – completely turns overATP supply every 13 seconds(!)
Potential fuels – “Metabolic omnivore”Free fatty acids (FFA)
• 70% in normal heartsGlucose
• Used in stressed/injured heartLactate
• Up to 60% of fetal energy production
![Page 13: DPP4-Inhibition and Coronary Artery Disease](https://reader036.fdocuments.in/reader036/viewer/2022062222/568163e6550346895dd54932/html5/thumbnails/13.jpg)
Responses to Injury and Insulin Resistance
RM Witteles and MB Fowler. J Am Coll Cardiol 2008; 51: 93-102
![Page 14: DPP4-Inhibition and Coronary Artery Disease](https://reader036.fdocuments.in/reader036/viewer/2022062222/568163e6550346895dd54932/html5/thumbnails/14.jpg)
Impact of Insulin Resistance on Myocardial Metabolism: Importance of FF Acid Generation
FFA=Free fatty acids.Adapted from Oliver MF et al. Lancet. 1994;343:155-158.
CV stress
Catechols, Cortisol
Lipolysis
Plasma FFA
Glucose
Insulin
Coronaryocclusion
Lysophospholipids
Ca2+ overload Enzyme loss
Glycolysis Glucose oxidation
Membranedamage
Arrhythmias
PhospholipidsTG
FFA
Acyl CoAAcylcarnitine
![Page 15: DPP4-Inhibition and Coronary Artery Disease](https://reader036.fdocuments.in/reader036/viewer/2022062222/568163e6550346895dd54932/html5/thumbnails/15.jpg)
Diabetic Hearts Rely Almost Completely on FFA
Belke et al. Am J Physiol Endocrinol Metab 2000; 279: E1104-E1113.
![Page 16: DPP4-Inhibition and Coronary Artery Disease](https://reader036.fdocuments.in/reader036/viewer/2022062222/568163e6550346895dd54932/html5/thumbnails/16.jpg)
Substrate Shifts in the Failing Heart
• Glucose metabolism: increased• FFA metabolism: decreased• Result: More efficient energy utilization• Fundamental point:
– These shifts are inhibited in the settingof insulin resistance!
• Therefore...– Insulin is important for the healthy heart
for transport and utilization of glucose– Insulin is even more important for the failing heart
which is more dependent on glucose metabolism.– Insulin resistance is particularly bad in the failing
heart.
![Page 17: DPP4-Inhibition and Coronary Artery Disease](https://reader036.fdocuments.in/reader036/viewer/2022062222/568163e6550346895dd54932/html5/thumbnails/17.jpg)
Diabetic hearts are less powerful... can be overcome with GLUT-4 overexpression
Belke et al. Am J Physiol Endocrinol Metab 2000; 279: E1104-E1113
![Page 18: DPP4-Inhibition and Coronary Artery Disease](https://reader036.fdocuments.in/reader036/viewer/2022062222/568163e6550346895dd54932/html5/thumbnails/18.jpg)
General features of insulin signal transduction pathways
R Muniyappa et al. Endocrine Reviews 2007; 28(5): 463-491.
INSULIN RESISTANCEINSULINSENSITIVE
![Page 19: DPP4-Inhibition and Coronary Artery Disease](https://reader036.fdocuments.in/reader036/viewer/2022062222/568163e6550346895dd54932/html5/thumbnails/19.jpg)
The concept of metabolic modulation to induce a shift towards glucose utilization may be a
particularly useful strategy for these patients.
![Page 20: DPP4-Inhibition and Coronary Artery Disease](https://reader036.fdocuments.in/reader036/viewer/2022062222/568163e6550346895dd54932/html5/thumbnails/20.jpg)
![Page 21: DPP4-Inhibition and Coronary Artery Disease](https://reader036.fdocuments.in/reader036/viewer/2022062222/568163e6550346895dd54932/html5/thumbnails/21.jpg)
AMI Pain-Related Burst of Catecholamine
1. Acts on adipose tissue to mobilize FFAs2. Acutely inhibits the release of insulin from the
pancreas3. AMI is diabetogenic . Causes hyperglycemia.
Vetter NJ. Lancet.1974;1:284-288.
4. Elevated FFAs are preferentially oxidized by skeletal and cardiac muscle, hence inhibiting the uptake and oxidation of glucose ( Breham A. Diabetes.2006; 55:136-40) and directly contributing to insulin resistance hyperglycemia (Whitteles RM. J Am Coll Cardiol.2008;51:93-102)
![Page 22: DPP4-Inhibition and Coronary Artery Disease](https://reader036.fdocuments.in/reader036/viewer/2022062222/568163e6550346895dd54932/html5/thumbnails/22.jpg)
Pain-Related Burst of Catecholamine
• Catecholamines increased glucose by promoting hepatic glycogenolysis
• Sustained β-adrenergic stimulation directly promotes insulin resistance by inhibition of insulin signaling at the level of protective kinases. Morisco C.Cardiovasc Res. 2007; 76:453-464.
• Early β-blockade can reduce FFA uptake by the failing myocardium Walhaus TR. Circ 2001;103:2441-2446 and lessen FFA accumulation in the ischemic-reperfused heart. Igarashi N. Circ J 006;70:1509-1514.
• β-blockade may have adverse hemodynamic consequences including cardiogenic shock and hypotension. Chen ZM.Lancet.2005;366:1622-1632. Giving β-blockade after 3 hours not of much benefit. Gersh BJ. JAMA 2005;293:979-986.
![Page 23: DPP4-Inhibition and Coronary Artery Disease](https://reader036.fdocuments.in/reader036/viewer/2022062222/568163e6550346895dd54932/html5/thumbnails/23.jpg)
Adverse Effects of FFAs in AMI
• Mechanisms:
Membrane-damaging detergent properties of FFAs . Oliver MF. Lancet.1994;343:155-158.
Increased oxygen demand. How OJ. Diabetes2006;55: 466-473.
The metabolic inefficiency leads to contractile abnormalities and adverse left ventricular remodeling. How OJ. Diabetes. 2006;55: 466-473.
![Page 24: DPP4-Inhibition and Coronary Artery Disease](https://reader036.fdocuments.in/reader036/viewer/2022062222/568163e6550346895dd54932/html5/thumbnails/24.jpg)
Changes in Oxygen Demand on Switching from Carbohydrate to Fatty Acid Metabolism
• Normal Heart- 11% increased in oxygen demand. Ashrafian H. Circulation. 2007;116:434-448.
• Diabetic Hearts perfused with FFAs- 85% increase with “pronounced oxygen wastage” coupled with decreased cardiac efficiency. How OJ. Diabetes2006;55: 466-473.
• This is due to mitochondrial uncoupling Essop F. Eur Heart J.2004;25:1765-1768 which underlies the FFA-induced increased in myocardial oxygen consumption Mjos OD. J Clin Invest,1971;50:1869-1873 and local heat production (Mjos OD. Scan J Clin Lab Invest. 1971;28:389-393)
![Page 25: DPP4-Inhibition and Coronary Artery Disease](https://reader036.fdocuments.in/reader036/viewer/2022062222/568163e6550346895dd54932/html5/thumbnails/25.jpg)
DPP-4 Inhibition and CAD
• The Heart in Diabetes-- Epidemiology-- Energy needs of the Heart
• The Role of Incretins in the Cardiovascular Continuum - Effects on risk factors, LVH ischemia,
AMI, remodeling, CHF and survival
• Mechanisms for GLP-1 Cardioprotection
![Page 26: DPP4-Inhibition and Coronary Artery Disease](https://reader036.fdocuments.in/reader036/viewer/2022062222/568163e6550346895dd54932/html5/thumbnails/26.jpg)
GLP-1R expression in mouse cardiac and vascular tissues
GLP-1R expression on cardiomyocytes
GLP-1R expression on endocardium
Ban K Circulation. 2008;117:2340-2350
GLP-1R expression on vascular endothelium, and SMCs
![Page 27: DPP4-Inhibition and Coronary Artery Disease](https://reader036.fdocuments.in/reader036/viewer/2022062222/568163e6550346895dd54932/html5/thumbnails/27.jpg)
The Cardiovascular Disease Continuum
VJ Dzau et al. Circulation 2006; 114: 2850-2870
![Page 28: DPP4-Inhibition and Coronary Artery Disease](https://reader036.fdocuments.in/reader036/viewer/2022062222/568163e6550346895dd54932/html5/thumbnails/28.jpg)
The Cardiovascular Disease Continuum
VJ Dzau et al. Circulation 2006; 114: 2850-2870
![Page 29: DPP4-Inhibition and Coronary Artery Disease](https://reader036.fdocuments.in/reader036/viewer/2022062222/568163e6550346895dd54932/html5/thumbnails/29.jpg)
GLP-1 and Cardiovascular Effects
• Weight loss associated with GPL-1 (exenatide) may have indirect benefit on CV risk including blood pressure, cholesterol levels , inflammatory markers and insulin resistance. Blonde L Diabetes Obes Metab 2006;8:436-447.
• In 217 patients from open-label extensions of various exenatide trials, modest benefit on certain CV risk factors. Klonoff DC. Curr Med Res Opin 2008;24:275-286.
- trend to decrease SBP; significant decrease DBP- decrease TG (-44.4 mg/dL), TC (-10.8 mg/dL) and LDL-C (-11.8
mg/dL) and increase HDL-C(8.5 mg/d/L)- ↓ CRP from 3.2 mg/L 1.35 mg/L
![Page 30: DPP4-Inhibition and Coronary Artery Disease](https://reader036.fdocuments.in/reader036/viewer/2022062222/568163e6550346895dd54932/html5/thumbnails/30.jpg)
Liraglutide
• Associated with weight loss• Associated with decrease in systolic blood
pressure• Decreases visceral fat• Favorable effect on CRP, etc
LEAD Programme, 2009
![Page 31: DPP4-Inhibition and Coronary Artery Disease](https://reader036.fdocuments.in/reader036/viewer/2022062222/568163e6550346895dd54932/html5/thumbnails/31.jpg)
GLP-1 Improves Endothelial Dysfunction Type 2 DM Patients with CAD
*P 0.05
Nystrom T. Am J Physiol Endocrinol Metab 287: E1209–E1215, 2004
![Page 32: DPP4-Inhibition and Coronary Artery Disease](https://reader036.fdocuments.in/reader036/viewer/2022062222/568163e6550346895dd54932/html5/thumbnails/32.jpg)
The Cardiovascular Disease Continuum
VJ Dzau et al. Circulation 2006; 114: 2850-2870
![Page 33: DPP4-Inhibition and Coronary Artery Disease](https://reader036.fdocuments.in/reader036/viewer/2022062222/568163e6550346895dd54932/html5/thumbnails/33.jpg)
GLP-1 Therapy vs GIK
• These effects are predicated on ambient
glucose concentration and are mitigated at plasma glucose concentrations <70 mg/dL, minimizing risks of hypoglycemia and the need for glucose infusion.
• Thus, the pharmacological properties of
GLP-1 are attractive as a means to stimulate myocardial glucose uptake during post-ischemic contractile dysfunction.
![Page 34: DPP4-Inhibition and Coronary Artery Disease](https://reader036.fdocuments.in/reader036/viewer/2022062222/568163e6550346895dd54932/html5/thumbnails/34.jpg)
Glucose-Dependent Actions of GLP-1in Patients With Type 2 Diabetes
![Page 35: DPP4-Inhibition and Coronary Artery Disease](https://reader036.fdocuments.in/reader036/viewer/2022062222/568163e6550346895dd54932/html5/thumbnails/35.jpg)
GLP-1 May Protect Against Infarction
• GPL-1 administered prior to ischemia can activated glycolysis and decrease pyruvate and lactate in the myocardium. GLP-1 can protect myocardium by reducing infarct size when given throughout ischemia and reperfusion
• This protective effect is in addition to activation of prosurvival kinases like PI3K /Akt.
• The prosurvival kinases are part of the Reperfusion Injury Salvage Kinase pathway (RISK pathway) associated with both precondtioning protection as well as protection against reperfusion injury.
• Thus GLP-1 may protect against infarction when given before ischemia (as a preconditioning mimetic) or at reperfusion
Bose AK Cardiovascular Drugs and Therapy 19 9–11 2005
![Page 36: DPP4-Inhibition and Coronary Artery Disease](https://reader036.fdocuments.in/reader036/viewer/2022062222/568163e6550346895dd54932/html5/thumbnails/36.jpg)
Myocardial infarction in hearts that have been subjected to 35 min of left main coronary artery occlusion followed by 120
min of reperfusion
AK Bose et al. Diabetes 2005; 54: 146-151.
![Page 37: DPP4-Inhibition and Coronary Artery Disease](https://reader036.fdocuments.in/reader036/viewer/2022062222/568163e6550346895dd54932/html5/thumbnails/37.jpg)
GLP-1 Decreases Myocardial Infarct Size
AK Bose et al. Diabetes 2005; 54: 146-151.
In vitro myocardialinfarct size
In vivo myocardialinfarct size
![Page 38: DPP4-Inhibition and Coronary Artery Disease](https://reader036.fdocuments.in/reader036/viewer/2022062222/568163e6550346895dd54932/html5/thumbnails/38.jpg)
Exenatide Reduces Infarct Size in a Porcine Model of Ischemia and Reperfusion Injury
Blue - nonthreatened myocardium, red - noninfarcted area within AAR, white - myocardial infarction. Timmers L. JACC 2009;53(6)501-510
Infa
rct S
ize
(% o
f AA
R)
Infa
rct S
ize
(% o
f LV
)
A Bp = 0.031 p = 0.047
C
PBS Exenatide
D
![Page 39: DPP4-Inhibition and Coronary Artery Disease](https://reader036.fdocuments.in/reader036/viewer/2022062222/568163e6550346895dd54932/html5/thumbnails/39.jpg)
Proof of Concept Clinical Study – AMI
• Small trial with GLP-1 in AMI and LV dysfunction after successful reperfusion – GLP-1 started after reperfusion.
• 21 patients with ST segment elevation MI and impaired LV systolic function (LVEF<40%) were undergoing primary PCI
Nikolaidis LA. Circ 2004:109:962-965
![Page 40: DPP4-Inhibition and Coronary Artery Disease](https://reader036.fdocuments.in/reader036/viewer/2022062222/568163e6550346895dd54932/html5/thumbnails/40.jpg)
Effects of GLP-1 in Patients with AMI and LV Dysfunction After Successful Reperfusion
• Primary objective - safety and efficacy of a 72-hour infusion of GLP-1 (1.5 pmol/kg per minute) added to background therapy in 10 patients with AMI and LV ejection fraction (EF) <40% after successful primary angioplasty compared with 11 control patients.
• Inclusion Critiria - Patients presenting within 6 hrs from symptom onset, with Killip class II–IV clinical presentation and LV ejection fraction (EF) <40%, who were treated with primary angioplasty
• Patient characteristics - Both groups had severe LV dysfunction at baseline (LVEF=29±2%).
• Parameters - Echocardiograms were obtained after reperfusion and after the completion of the GLP-1 infusion.
Nikolaidis LA. Circ 2004:109:962-965
![Page 41: DPP4-Inhibition and Coronary Artery Disease](https://reader036.fdocuments.in/reader036/viewer/2022062222/568163e6550346895dd54932/html5/thumbnails/41.jpg)
Changes in LVEF and in regional wall motion score at the per-infarct zone after 72 hours of rGLP-1 infusion
LA Nikolaidis et al. Circulation 2004; 109: 962-965.
![Page 42: DPP4-Inhibition and Coronary Artery Disease](https://reader036.fdocuments.in/reader036/viewer/2022062222/568163e6550346895dd54932/html5/thumbnails/42.jpg)
Results- Mortality/MorbidityrGLP-1 TreatedN=10
Controls N=11
p value
In-Hospital Mortality Rate
1 (10%) 3 (27%)
CV Death 0 2 (18%); VF, Cardiogenic Shock
Length of Hospital Stay (days)
6.1 ± 1.3 9.8 ± 1.5 0.02
CCU Days 3.1 ± 4 5.1 ± 1.0
![Page 43: DPP4-Inhibition and Coronary Artery Disease](https://reader036.fdocuments.in/reader036/viewer/2022062222/568163e6550346895dd54932/html5/thumbnails/43.jpg)
Conclusion• GLP-1 infusion improved regional and global LV function
in patients with AMI and severe systolic dysfunction after successful primary angioplasty.
• rGLP-1 may contribute to improved outcomes through non–glucose-dependent mechanisms. These include reductions in plasma NEFA levels that have been
implicated in arrhythmogenesis. Kavianipour M Peptides 2003:24:560-578.
• rGLP-1 may improve endothelial function and microcirculatory integrity, as suggested by the higher peak creatine phosphokinase, consistent with greater washout, in the rGLP-1–treated patients, despite comparable baseline regional and global LV dysfunction
in both groups.
![Page 44: DPP4-Inhibition and Coronary Artery Disease](https://reader036.fdocuments.in/reader036/viewer/2022062222/568163e6550346895dd54932/html5/thumbnails/44.jpg)
The Cardiovascular Disease Continuum
VJ Dzau et al. Circulation 2006; 114: 2850-2870
![Page 45: DPP4-Inhibition and Coronary Artery Disease](https://reader036.fdocuments.in/reader036/viewer/2022062222/568163e6550346895dd54932/html5/thumbnails/45.jpg)
GLP-1 Improves the Failing Heart
• In failing myocardium, Shannon’s group reported beneficial effects of LV contractile function.
• -- in a canine model of pacing-induced dilated CM, 48 hour infusion of GLP-1 improved myocardial insulin sensitivity and glucose uptake; increased SV and CO, and decreased LVED volume, HR and systemic vascular resistance. Nikolaidis LA. Circulation 2004; 110:955-961.
• -- in a canine model of myocardial stunning, GLP-1 improved regional contractile function. Nikolaidis LA. J Pharmacol Exp Ther 2005; 312:303-308.
![Page 46: DPP4-Inhibition and Coronary Artery Disease](https://reader036.fdocuments.in/reader036/viewer/2022062222/568163e6550346895dd54932/html5/thumbnails/46.jpg)
Hemodynamic Effects of Continuous infusion of rGLP-1
• Failing heart has a preference for glucose as its metabolic substrate
• Examine impact rGLP-1 on LV and systemic hemodynamics and myocardial substrate uptake
• - 16 conscious dogs with advanced DCM vs 8 controls
• May provide a mechanism for overcoming myocardial insulin resistance and enhancing myocardial glucose uptake.
Nikolais LA Circulation 2004;110:955-961
![Page 47: DPP4-Inhibition and Coronary Artery Disease](https://reader036.fdocuments.in/reader036/viewer/2022062222/568163e6550346895dd54932/html5/thumbnails/47.jpg)
rGLP-1 improves myocardial glucose uptake, oxygen consumption, and CBF responses at matched levels of hyperinsulinemia, consistent with insulinomimetic effect
LA Nikolaidis et al. Circulation 2004; 110: 955-961
![Page 48: DPP4-Inhibition and Coronary Artery Disease](https://reader036.fdocuments.in/reader036/viewer/2022062222/568163e6550346895dd54932/html5/thumbnails/48.jpg)
Proof of Concept Clinical Study
• 12 patients, chronic HF (NYHA III & IV) • 5 weeks of chronic GLP-1 infusion increased LVEF
from 21% to 27%, augmented maximum myocardial oxygen consumption and improved the 6-minute walk test and QOL in both diabetic and non-diabetic patients.
• No significant changes in any of the parameters in the control patients on standard therapy.
• Benefits were seen in both diabetic both diabetic and non-diabetic patients. Sokos GG. J Card Fail 2006;12:694-699.
![Page 49: DPP4-Inhibition and Coronary Artery Disease](https://reader036.fdocuments.in/reader036/viewer/2022062222/568163e6550346895dd54932/html5/thumbnails/49.jpg)
GLP-1 Therapy improvesHeart Failure –Class III-IV
GG Sokos. J Cardiac Fail 2006; 12(9): 694-699.
![Page 50: DPP4-Inhibition and Coronary Artery Disease](https://reader036.fdocuments.in/reader036/viewer/2022062222/568163e6550346895dd54932/html5/thumbnails/50.jpg)
GLP-1 Therapy Improves Heart Failure
GG Sokos. J Cardiac Fail 2006; 12(9): 694-699.
![Page 51: DPP4-Inhibition and Coronary Artery Disease](https://reader036.fdocuments.in/reader036/viewer/2022062222/568163e6550346895dd54932/html5/thumbnails/51.jpg)
The Cardiovascular Disease Continuum
VJ Dzau et al. Circulation 2006; 114: 2850-2870
Survival???
![Page 52: DPP4-Inhibition and Coronary Artery Disease](https://reader036.fdocuments.in/reader036/viewer/2022062222/568163e6550346895dd54932/html5/thumbnails/52.jpg)
SHHF rats randomized to receive intraperintoneal continuous infusion of GLP-1 had better survival compared with control
I Poornima. Circ Heart Fail 2008; 1: 153-160
![Page 53: DPP4-Inhibition and Coronary Artery Disease](https://reader036.fdocuments.in/reader036/viewer/2022062222/568163e6550346895dd54932/html5/thumbnails/53.jpg)
GLP-1 treatment was associated with significantly less myocyte apoptosis. There was no difference in nonmyocyte apoptosis.
I Poornima. Circ Heart Fail 2008; 1: 153-160
![Page 54: DPP4-Inhibition and Coronary Artery Disease](https://reader036.fdocuments.in/reader036/viewer/2022062222/568163e6550346895dd54932/html5/thumbnails/54.jpg)
Mechanisms for GLP-1 Cardioprotection
• Improvement of risk factors – weight loss, BP reduction, improved lipids and PPG reduction
• Improved vascular FMD.• Increases myocardial glucose uptake• Recruitment of intracellular signaling pathways
involving Akt, Erk1/2, p70S6K and AMPK as well as the downstream phosphorylation and inhibition of the pro-apoptotic protein BAD, etc.
• Decreased myocyte apoptosis• Strongly cardioprotective in multiple preclinical
models
![Page 55: DPP4-Inhibition and Coronary Artery Disease](https://reader036.fdocuments.in/reader036/viewer/2022062222/568163e6550346895dd54932/html5/thumbnails/55.jpg)
Incretin-based therapies inType 2 Diabetes Mellitus
![Page 56: DPP4-Inhibition and Coronary Artery Disease](https://reader036.fdocuments.in/reader036/viewer/2022062222/568163e6550346895dd54932/html5/thumbnails/56.jpg)
Cardiovascular risk factors and DPP-4 inhibition
• Effective control of PPG• Reduction of postprandial lipids, especially
chylomicrons and TGs• Body weight – no effect or slight reduction• Preclinical data- modest but significant
cardioprotection in vivo
![Page 57: DPP4-Inhibition and Coronary Artery Disease](https://reader036.fdocuments.in/reader036/viewer/2022062222/568163e6550346895dd54932/html5/thumbnails/57.jpg)
DPP-4 Inhibition and CAD
• The Heart in Diabetes-- Epidemiology-- Energy needs of the Heart
• The Role of Incretins in the Cardiovascular Continuum - Effects on risk factors, LVH ischemia,
AMI, remodeling, CHF and survival
• Mechanisms for GLP-1 Cardioprotection